ArticleBMC pulmonary medicine2026
Plasma TIM-1 concentration: correlation with cytokines in pulmonary tuberculosis patients and development of a predictive model.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo investigate the dynamic expression of T-cell immunoglobulin and mucin domain molecule-1 (TIM-1) in pulmonary tuberculosis (PTB) patients at various stages, and examine possible relationships with IFN-γ and IL-17, to elucidate the potential roles in PTB pathogenesis. In addition, we aimed to assess the feasibility of using TIM-1 combined with IFN-γ and IL-17 as a biomarker for PTB diagnosis.
methodsPlasma samples were collected from 60 PTB patients, 50 latent tuberculosis infection (LTBI) patients, and 50 healthy controls at the First Affiliated Hospital of Xinjiang Medical University between February and November 2023. The concentrations of TIM- 1, IFN-γ, and IL-17 in plasma were quantified using ELISA. Correlation and Logistic regression analyses were conducted, followed by the construction of a predictive model.
resultsSignificantly higher plasma concentrations of TIM-1 and IL-17 and reduced levels of IFN-γ were observed in PTB patients compared to LTBI subjects and healthy controls. A positive correlation was found between TIM-1 and IL-17 levels in PTB patients. Receiver operating characteristic (ROC) curve analysis demonstrated that TIM-1 exhibited moderate diagnostic performance, with a cutoff value of 22.3 pg·ml
conclusionsPlasma TIM-1 concentration was significantly elevated in PTB patients and non-significantly raised in LTBI suggesting possible roles in promoting inflammation and modulating Th17 responses, potentially influencing mycobacterial clearance and perhaps disease progression. This highlights the potential importance of TIM-1 in tuberculous inflammatory processes, immune regulation, and its utility in early diagnostics, suggesting it may be a novel therapeutic target in PTB. These findings are preliminary and require further validation in larger, multicenter studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.